ArticleTranslational breast cancer research : a journal focusing on translational research in breast cancer2025
Combined treatment of inetetamab plus pyrotinib and vinorelbine in managing advanced HER2-positive breast cancer patients (ILLUMINE): a multicenter, retrospective, real-world study.
Article in Translational breast cancer research : a journal focusing on translational research in breast cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Development and validation of explainable machine learning models for the prediction of survival in patients with M1 breast cancer.Gland surgery · 2026Article
- Diet, hormones, and breast cancer: biomarker-guided assessment of risk and prognosis.Frontiers in immunology · 2026Review
- Inetetamab-Based Regimens for Patients with HER2-Positive Metastatic Breast Cancer: A Real-World Retrospective Study.Breast cancer (Dove Medical Press) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Breast cancer is the most common tumor among women worldwide, which human epidermal growth factor receptor 2 (HER2)-positive subtype accounts for approximately 15-20%. Although anti-HER2 agents have already diversified in recent years, a highly effective and more affordable treatment option is urgently needed. Inetetamab is a new antibody exhibiting efficacy in managing HER2-positive advanced breast cancer (ABC) through antibody-dependent cellular cytotoxicity (ADCC). Pyrotinib is a second-line treatment specifically targeting HER2. Given that pyrotinib could exhibit strong HER2 antagonism and synergize with monoclonal antibodies to boost ADCC effect, herein we investigated the effects and safety of first to third line of combined treatments utilizing inetetamab plus vinorelbine and pyrotinib in dealing with HER2-positive ABC. Methods: This is a multicenter, retrospective, real-world study. During the period of July 2020 to October 2023, 76 participants at 17 centers with HER2-positive ABC received the triple regimen and were evaluated for progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and clinical benefit rate (CBR). Data regarding treatment-associated adverse events (TAAEs) were also collected. Results: The median age of the participants enrolled was 53 years. Among the participants, 53 (69.7%) were diagnosed to suffer from visceral metastases, while 35 (46.1%) possessed hormone receptor-positive lesions. The median PFS (mPFS) of the cohort was 10.03 months [95% confidence interval (CI): 6.80 to 13.27]. The ORR and CBR were respectively 61.8% (47/76) and 97.4% (74/76). The TAAE with highest incidence was diarrhea (77.6%). Grades III and IV TAAEs with highest incidences were leukopenia (19.7%), neutropenia (19.7%), and diarrhea (17.1%). No severe TAAEs were observed during the investigation. Conclusions: The triple regimen of inetetamab plus pyrotinib and vinorelbine exhibited promising therapeutic effects and was tolerable for participants with HER2-positive ABC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.